<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSES: <z:chebi fb="0" ids="25297">Methylenetetrahydrofolate</z:chebi> reductase (MTHFR) plays a key role in <z:chebi fb="3" ids="37445">folate</z:chebi> metabolism, and <z:chebi fb="3" ids="37445">folate</z:chebi> is implicated in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> by its role in DNA methylation, repair, and synthesis </plain></SENT>
<SENT sid="1" pm="."><plain>We analyzed the impact of MTHFR C677T polymorphism in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in a region of the Tenerife Island whose population has a history of genetic isolation and a low genetic variability </plain></SENT>
<SENT sid="2" pm="."><plain>This allows analyzing the effects of the polymorphism that are not due to interactions with different genetic variants </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Genomic DNA of 50 Spanish <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients and 103 controls was analyzed by PCR/RFLP and sequencing </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The T allele is more frequent in controls than in patients (P &lt; 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>The variant (T) carriers displayed significant odds ratio values for the CT heterozygotes (P = 0.026) and even when grouping heterozygote (CT) and homozygotes (TT) (P = 0.015) </plain></SENT>
<SENT sid="6" pm="."><plain>Patients carriers of the variant T (CT y TT) show a higher survival rate after chemotherapy than the CC homozygotes (log rank; P = 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: The MTHRF C677T variant has a protective effect on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> development in a population with low allelic variability and an optimal intake of <z:chebi fb="9" ids="27470">folic acid</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, patients carrying the variant (T) show a better prognosis after <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi>/folinic acid-based chemotherapy </plain></SENT>
</text></document>